Members Login
Medical NewsEPG Search
Frequent Searches:
Browse Other Languages
Spanish Drug Data (España)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
German Drug Data (Deutsch)
Norwegian Drug Data (Norge)
Netherlands Drug Data (Nederlands)
Swedish Drug Data (Sverige)
YouTube - Featured Content
Want to submit or suggest content for the epgonline.org YouTube Clinical channel?
Contact us here
epgonline.org is not responsible for content on any 3rd party website
Are you a Doctor or Healthcare Professional? Authorise Viewing
Please register to access disease diagnosis, patient management, physician tools.
By viewing the content of this web page you are both confirming your status as a healthcare professional and agreeing to our terms of use.
Change language
Current language database:
United Kingdom
Medicine information : RENAGEL 800 mg Film-Coated Tablets
| Drug class description : | Treatment of hyperphosphatemia |
| Generic Name : | Sevelamer |
| Drug description : | Film-coated tablets The off-white, oval tablets are imprinted with Renagel 800 on one side. |
| Presentation : | Each tablet contains 800 mg sevelamer. |
| Indications : | Hyperphosphataemia in haemodialysis. |
| Adult Dosage : | Adults and elderly (> 65 years) For patients who are not on phosphate binders, dosage is determined individually based on serum phosphate concentration as indicated see below: Serum phosphate level in patients not on phosphate binders = 1.94 – 2.42 mmol/l (6-7.5 mg/dl) Starting dose of Renagel 800 mg tablets 3 times a day x 1 tablets Serum phosphate level in patients not on phosphate binders = > 2.42 mmol/l >7.5 mg/dl) Starting dose of Renagel 800 mg tablets 3 times a day x 2 tablets If Renagel is prescribed as an alternative phosphate binder, Renagel should be given in equivalent doses on a mg weight basis compared to the patient's previous calcium based phosphate binder. Serum phosphate levels should be closely monitored and the dose of Renagel adjusted accordingly with the goal of lowering serum phosphate to 1.94 mmol/l (6 mg/dl) or less. Serum phosphate should be tested every two to three weeks until a stable serum phosphate level is reached and on a regular basis thereafter. The dose range may vary between 1 and 5 800 mg tablets per meal. The average actual daily dose used in the chronic phase of a one year clinical study was 7 grams of sevelamer. Patients should take Renagel with meals and adhere to their prescribed diets. The tablets must be swallowed whole. Do not chew. |
| Child Dosage : | The safety and efficacy of this product has not been established in patients below the age of 18 years. |
| Elderly Dosage : | See Adult Dosage |
| Contra Indications : | • Hypophosphataemia or bowel obstruction. • Hypersensitivity to sevelamer or to any of the excipients in the product. |
| Special Precautions : | Efficacy and safety of Renagel has not been studied in children, in predialysis patients or in patients receiving peritoneal dialysis treatment. The safety and efficacy of Renagel has not been studied in patients with swallowing disorders, untreated or severe gastroparesis, and retention of gastric contents. Renagel should only be used in these patients following careful assessment of benefit and risks. Efficacy and safety of Renagel has not been studied in patients with active inflammatory bowel disease, gastrointestinal motility disorders, abnormal or irregular bowel motion and patients with a history of major gastrointestinal surgery. Consequently, caution should be exercised when Renagel is used in patients with these disorders. In very rare cases, intestinal obstruction and ileus/subileus have been observed in patients during treatment with Renagel. Constipation may be a preceding symptom. Patients who are constipated should be monitored carefully while being treated with Renagel. Renagel treatment should be re-evaluated in patients who develop severe constipation. Renagel alone is not indicated for the control of hyperparathyroidism. In patients with secondary hyperparathyroidism Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels. Patients with renal insufficiency may develop hypocalcaemia or hypercalcaemia. Renagel does not contain calcium. Serum calcium levels should be monitored as is done in normal follow-up of a dialysis patient. Elemental calcium should be given as a supplement in case of hypocalcaemia. Depending on diet intake and the nature of end stage renal failure, dialysis patients may develop low vitamin A, D, E and K levels. Therefore, in patients not taking these vitamins, monitoring vitamin A, D and E levels and assessing vitamin K status through the measurement of thromboplastin time should be considered and the vitamins should be supplemented if necessary. There is at present insufficient data to exclude the possibility of folate deficiency during long term Renagel treatment. Serum chloride may increase during Renagel treatment as chloride may be exchanged for phosphorus in the intestinal lumen. Although no clinically significant serum chloride increase has been observed in the clinical studies, serum chloride should be monitored as is done in the routine follow-up of a dialysis patient. One gram of Renagel contains approximately 180 mg (5.1mEq) chloride. Patients with chronic renal failure are predisposed to developing metabolic acidosis. Worsening of acidosis has been reported upon switching from other phosphate binders to sevelamer in a number of studies where lower bicarbonate levels in the sevelamer-treated patients compared to patients treated with calcium-based binders were observed. Closer monitoring of serum bicarbonate levels is therefore recommended. Very rare cases of hypothyroidism have been reported in patients co-administered Renagel and Levothyroxine. Closer monitoring of TSH levels is therefore recommended in patients receiving both drugs. As data on the chronic use of sevelamer for over one year are not yet available, potential absorption and accumulation of sevelamer during long-term chronic treatment cannot be totally excluded. |
| Interactions : | Interaction studies have not been conducted in patients on haemodialysis. In interaction studies in healthy volunteers, Renagel had no effect on the bioavailability of digoxin, warfarin, enalapril or metoprolol. However, the bioavailability of ciprofloxacin was decreased by approximately 50% when co-administered with Renagel in a single dose study. Consequently, Renagel should not be taken simultaneously with ciprofloxacin. Renagel may affect the bioavailability of other medicinal products. Reduced levels of cyclosporine and mycophenolate mofetil have been reported in transplant patients when coadministered with Renagel without any clinical consequences (i.e graft rejection). The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of mycophenolate mofetil and cyclosporine should be considered during the use of combination and after its withdrawal. When administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after Renagel, or the physician should consider monitoring blood levels. In animal studies, co-administration of a single dose of Renagel with verapamil, quinidine, calcitriol, tetracycline, warfarin, valproic acid, digoxin, propranolol, estrone and L-thyroxin did not alter peak serum concentrations or area under the curve for serum concentrations of these products. Pregnancy and lactation The safety of Renagel has not been established in pregnant or lactating women. In animal studies there was no evidence that sevelamer induced embryo-foetal toxicity. Renagel should only be given to pregnant or lactating women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus or infant. |
| Adverse Reactions : | In a parallel design study involving 202 patients with treatment duration of 52 weeks, the most frequently occurring ( 5% of patients) undesirable effects possibly or probably related to Renagel were all in the gastrointestinal disorders system organ class. Data possibly or probably related to Renagel from this study and from uncontrolled clinical trials involving 384 patients are listed by frequency in the table below. The reporting rate is classified as very common (>1/10), common (>1/100, <1/10), uncommon (>1/1,000, <1/100), rare (>1/10,000, <1/1,000), very rare ( <1/10,000), including isolated reports. Gastrointestinal Disorders: Very common : Nausea, vomiting, abdominal pain, constipation, diarrhoea, dyspepsia, Common : Flatulence Nervous system disorders: Very common: Headache Vascular disorders: Very common : Hypotension, hypertension General disorders and administration site conditions: Very common : Pain. Skin and subcutaneous disorders: Very common : Pruritis, Common: Rash. Infections and infestations: Common : Pharyngitis Most of these events are commonly observed in patients Stage 5 Chronic Kidney Disease and are not necessarily attributable to Renagel. Post-marketing experience: In very rare cases, intestinal obstruction and ileus/subileus have been observed in patients during treatment with Renagel. |
| Manufacturer : | Genzyme |
| Drug Availability : | (POM) |
Free registration to access disease diagnosis, patient management, physician tools.
Only registered users have access to the full EPG Online Knowledge Base including drug search tools, interactive disease Knowledge Centres via the EPG Knowledge Library - with clinical and evidence based physician and research tools, MiMedia (build your own clinical media collection with everything from key opinion leader essays to mode of action videos and other multi-media content), the EPG Survey panel, health news updates and much much more.
Already Registered?
Please log-in now using our member login box.
Not a member?
Don't worry, registration is quick and FREE! We welcome all Healthcare professionals, doctors, nurses and medical students.
Register today to have full access to a wealth of drug data, educational and evidence based interactive guides across all major therapeutic areas, disease management, and clinical tools.
As a practicing Healthcare professional, you can also opt-in to join our market research panel – www.epgsurvey.com – and get paid for sharing your expert clinical opinions!
REGISTER today it only takes a minute! and it's FREE
Having problems?
Use our forgotten password facility or email us at: contact@epgonline.org